Cromolyn sodium delays symptoms of ALS in mice, study reveals
The US FDA-approved anti-inflammatory drug cromolyn sodium has been demonstrated to delay disease progression in an ALS mouse model.
Browsing: ALS
Phase II/III trials of umibecestat to discontinue for Alzheimer’s disease: industry news round-up
This week in industry we’re taking a look at the discontinuation of umibecestat and Acthar® Gel for Alzheimer’s and ALS, respectively, as well as the drug discovery shift from the amyloid approach in the Alzheimer’s field.
New drug may limit progression of genetic form of ALS
A preliminary clinical study has demonstrated that the experimental drug tofersen may be effective in the treatment of a genetic form of ALS.
AAN 2019: Does playing soccer increase your risk of ALS?
Researchers have demonstrated that there may be a link between playing professional soccer and developing ALS. Soccer players studied were almost twice as likely to develop the disease than the general population.
Build-up of RNA-binding proteins found in individuals with ALS and dementia
Researchers have revealed that RNA-binding proteins accumulate in the brains of people with non-heritable amyotrophic lateral sclerosis and frontotemporal dementia.
Investigational therapy for ALS now in clinical trials
A potential new therapeutic for inherited amyotrophic lateral sclerosis, which extended survival and reversed fatal neuromuscular damage in rodents, has entered Phase I/II clinical trials.
